IRIS
LANDI, DORIANA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.140
AS - Asia 1.865
EU - Europa 1.358
SA - Sud America 371
AF - Africa 26
Continente sconosciuto - Info sul continente non disponibili 3
OC - Oceania 3
Totale 8.766
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.101
SG - Singapore 984
IT - Italia 644
BR - Brasile 312
HK - Hong Kong 255
CN - Cina 232
IE - Irlanda 195
KR - Corea 176
RU - Federazione Russa 121
DE - Germania 86
VN - Vietnam 79
NL - Olanda 55
GB - Regno Unito 54
UA - Ucraina 35
CA - Canada 26
FI - Finlandia 26
FR - Francia 24
SE - Svezia 24
AR - Argentina 23
AT - Austria 23
JP - Giappone 21
IN - India 19
CH - Svizzera 15
IQ - Iraq 15
TR - Turchia 15
ES - Italia 14
PL - Polonia 12
EC - Ecuador 11
BD - Bangladesh 10
ID - Indonesia 10
GR - Grecia 9
ZA - Sudafrica 9
CZ - Repubblica Ceca 8
EG - Egitto 8
CL - Cile 7
MX - Messico 7
MY - Malesia 7
PK - Pakistan 7
UZ - Uzbekistan 7
CO - Colombia 6
PY - Paraguay 6
IR - Iran 5
KG - Kirghizistan 5
RO - Romania 4
PE - Perù 3
SA - Arabia Saudita 3
AU - Australia 2
AZ - Azerbaigian 2
JO - Giordania 2
KE - Kenya 2
MA - Marocco 2
NG - Nigeria 2
NI - Nicaragua 2
PA - Panama 2
PH - Filippine 2
VE - Venezuela 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AE - Emirati Arabi Uniti 1
BA - Bosnia-Erzegovina 1
BE - Belgio 1
BG - Bulgaria 1
BH - Bahrain 1
BQ - ???statistics.table.value.countryCode.BQ??? 1
BY - Bielorussia 1
DK - Danimarca 1
DM - Dominica 1
DZ - Algeria 1
EE - Estonia 1
ET - Etiopia 1
EU - Europa 1
GD - Grenada 1
GE - Georgia 1
GI - Gibilterra 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LT - Lituania 1
NZ - Nuova Zelanda 1
OM - Oman 1
QA - Qatar 1
RS - Serbia 1
TJ - Tagikistan 1
TN - Tunisia 1
TW - Taiwan 1
UY - Uruguay 1
Totale 8.766
Salva come PNG Salva come JPEG
Città #
Wilmington 1.234
Houston 970
Woodbridge 527
Singapore 464
New York 350
Hong Kong 253
Chandler 198
Fairfield 179
Dublin 176
Beijing 132
Ashburn 107
Rome 95
Santa Clara 84
Los Angeles 77
Ann Arbor 65
Dallas 64
Seattle 58
Medford 57
Roebling 55
The Dalles 54
Milan 51
Cambridge 50
Buffalo 41
Ho Chi Minh City 36
São Paulo 34
San Jose 30
Dearborn 29
Moscow 29
Lawrence 28
Turin 22
Naples 21
North Bergen 21
Chicago 20
San Diego 19
Nuremberg 17
Redondo Beach 16
Lappeenranta 15
Jacksonville 14
Hanoi 13
Piove di Sacco 13
Tokyo 13
Council Bluffs 12
Creede 12
Bologna 11
London 11
Munich 11
Florence 10
Jakarta 10
San Francisco 10
Seoul 10
Tampa 10
Belo Horizonte 9
Montreal 9
Mülheim 9
Palo Alto 9
Warsaw 9
Atlanta 8
Bari 8
Brno 8
Brooklyn 8
Elk Grove Village 8
Inverigo 8
Norwalk 8
Redwood City 8
Vienna 8
Denver 7
Johannesburg 7
Salt Lake City 7
Toronto 7
Brasília 6
Chennai 6
Colorado Springs 6
Helsinki 6
Lodi 6
Palermo 6
Phoenix 6
Rio de Janeiro 6
Sterling 6
Zhengzhou 6
Billings 5
Boardman 5
Buenos Aires 5
Genoa 5
Kilburn 5
Kuala Lumpur 5
Nanjing 5
Quito 5
Tashkent 5
Terni 5
Trieste 5
Verona 5
Ankara 4
Athens 4
Bogotá 4
Boston 4
Detroit 4
Guangzhou 4
Haiphong 4
Karbala 4
Lausanne 4
Totale 6.139
Salva come PNG Salva come JPEG
Nome #
No evidence of beneficial effects of plasmapheresis in natalizumab-associated PML 494
TRPV1 polymorphisms and risk of interferon β-induced flu-like syndrome in patients with relapsing-remitting multiple sclerosis 479
Fingolimod reduces the clinical expression of active demyelinating lesions in MS 418
Delayed treatment of MS is associated with high CSF levels of IL-6 and IL-8 and worse future disease course 332
Abortion induces reactivation of inflammation in relapsing-remitting multiple sclerosis 318
Fingolimod reduces the clinical expression of active demyelinating lesions in MS 312
Platelet-derived growth factor predicts prolonged relapse-free period in multiple sclerosis 303
Safety, tolerability and effectiveness of dimethyl fumarate in multiple sclerosis: an independent, multicenter, real-world study 301
Miscarriage induces reactivation of inflammation in relapsing-remitting multiple sclerosis 292
null 289
Safety and Efficacy of Dimethyl Fumarate in Multiple Sclerosis: An Italian, Multicenter, Real-World Study 287
Validity of the Italian multiple sclerosis neuropsychological screening questionnaire 286
Treatment with Dimethyl Fumarate Enhances Cholinergic Transmission in Multiple Sclerosis 179
Management of flu-like syndrome with cetirizine in patients with relapsing-remitting multiple sclerosis during therapy with interferon beta: Results of a randomized, cross-over, placebo-controlled pilot study 160
Adherence to social distancing and use of personal protective equipment and the risk of SARS-CoV-2 infection in a cohort of patients with multiple sclerosis 149
Switch from sequestering to anti-CD20 depleting treatment: disease activity outcomes during wash-out and in the first 6 months of ocrelizumab therapy 142
Mild clinical manifestations of SARS-CoV-2 related pneumonia in two patients with multiple sclerosis under treatment with ocrelizumab 138
Cerebrospinal fluid lactate is associated with multiple sclerosis disease progression 127
Functional assessment of outer and middle macular layers in multiple sclerosis 126
T-cell responses to SARS-CoV-2 in Multiple Sclerosis patients treated with ocrelizumab healed from COVID-19 with absent or low anti-Spike antibody titers 116
B- and T-Cell Responses After SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Receiving Disease Modifying Therapies: Immunological Patterns and Clinical Implications 108
Assessment of macular function by multifocal electroretinogram in patients with multiple sclerosis treated with fingolimod 100
Complex Rearrangement of the Entire Retinal Posterior Pole in Patients with Relapsing Remitting Multiple Sclerosis 95
Defining the course of tumefactive multiple sclerosis: A large retrospective multicentre study 93
Correction to: Validity of the Italian multiple sclerosis neuropsychological screening questionnaire 90
Cortical ischemic lesion burden measured by DIR is related to carotid artery disease severity 85
NEDA-3 achievement in early highly active relapsing remitting multiple sclerosis patients treated with Ocrelizumab or Natalizumab 84
Cladribine vs other drugs in MS: Merging randomized trial with real-life data 82
Assisted Reproductive Technology and Disease Management in Infertile Women with Multiple Sclerosis 79
Patient's point of view on the use of telemedicine in multiple sclerosis: a web-based survey 78
COVID-19: dealing with a potential risk factor for chronic neurological disorders 74
Validity of the minimal assessment of cognitive function in multiple sclerosis (MACFIMS) in the Italian population 73
Cognition is related to resting-state small-world network topology: an magnetoencephalographic study 72
Anti-HBs titers are not decreased after treatment with oral Cladribine in patients with Multiple Sclerosis vaccinated against Hepatitis B virus 69
Complex epileptic palilalia: a case report 67
Breakthrough SARS-CoV-2 infections after COVID-19 mRNA vaccination in MS patients on disease modifying therapies during the Delta and the Omicron waves in Italy 67
Risk Assessment of Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis Patients during 1 Year of Ocrelizumab Treatment 67
What happens after fingolimod discontinuation? A multicentre real-life experience 66
Predictors of lymphocyte count recovery after dimethyl fumarate-induced lymphopenia in people with multiple sclerosis 64
Safety of Natalizumab infusion in multiple sclerosis patients during active SARS-CoV-2 infection 62
Exit strategies for "needle fatigue" in multiple sclerosis: a propensity score-matched comparison study 61
Exposure to natalizumab throughout pregnancy: effectiveness and safety in an Italian cohort of women with multiple sclerosis 60
Association of vitamin D serum levels and vitamin D supplementation with B cell kinetics and disease activity in Multiple Sclerosis patients treated with ocrelizumab: an Italian multi-center study 59
A multiparametric score for assessing the individual risk of severe Covid-19 among patients with Multiple Sclerosis 54
Ovarian reserve in patients with multiple sclerosis: A systematic review and meta-analysis 53
Cortico-muscular coherence as an index of fatigue in multiple sclerosis 53
A specific anti-COVID-19 BNT162b2 vaccine-induced early innate immune signature positively correlates with the humoral protective response in healthy and multiple sclerosis vaccine recipients 53
Multifocal Electroretinogram Photopic Negative Response: A Reliable Paradigm to Detect Localized Retinal Ganglion Cells' Impairment in Retrobulbar Optic Neuritis Due to Multiple Sclerosis as a Model of Retinal Neurodegeneration 53
Cerebral restorative plasticity from normal ageing to brain diseases: a "never ending story" 52
Executive functioning in relapsing-remitting multiple sclerosis patients without cognitive impairment: A task-switching protocol 51
The role of ethnicity and native-country income in multiple sclerosis: the Italian multicentre study (MS-MigIT) 51
Thalamocortical sensorimotor circuit in multiple sclerosis: an integrated structural and electrophysiological assessment 51
Predictors of Cladribine Effectiveness and Safety in Multiple Sclerosis: A Real-World, Multicenter, 2-Year Follow-Up Study 50
First therapy choice in newly diagnosed Multiple Sclerosis patients: A multicenter Italian study 50
Real world experience with teriflunomide in multiple sclerosis: the TER-Italy study 49
Diagnostic value of JC polyomavirus viruria, viremia, serostatus and microRNA expression in multiple sclerosis patients undergoing immunosuppressive treatment 48
Influence of Previous Disease-Modifying Drug Exposure on T-Lymphocyte Dynamic in Patients With Multiple Sclerosis Treated With Ocrelizumab 48
Intra-cortical connectivity in multiple sclerosis: a neurophysiological approach 47
Choriocapillaris Integrity in Relapsed Central Serous Chorioretinopathy in a Patient Treated With Fingolimod for Multiple Sclerosis: New Insights From Optical Coherence Tomography Angiography 47
Skin Thickening of the Scalp and High Signal Intensity of Dentate Nucleus in Multiple Sclerosis: Association With Linear Versus Macrocyclic Gadolinium-Based Contrast Agents Administration 47
Oxidative Stress Related to Iron Metabolism in Relapsing Remitting Multiple Sclerosis Patients With Low Disability 46
Maternal and fetal outcomes in an Italian multicentric cohort of women with multiple sclerosis exposed to dimethyl fumarate during pregnancy 45
Maternal Multiple Sclerosis and Offspring’s Developmental and Behavioral Profile: A Case-control Study 45
Real-World 24-Month Outcomes of Ofatumumab in Relapsing Multiple Sclerosis: Efficacy, Safety, and the Impact of Frailty 44
Diffusion-weighted lesions after carotid artery stenting are associated with cognitive impairment 44
Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies 43
Oral fingolimod reduces glutamate-mediated intracortical excitability in relapsing???remitting multiple sclerosis 42
COVID-19 vaccine hesitancy among Italian people with multiple sclerosis 42
Phenotypic characterization of the placenta from women with Multiple Sclerosis exposed to Natalizumab during pregnancy. 41
Efficacy of different rituximab therapeutic strategies in patients with neuromyelitis optica spectrum disorders 41
SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort study 41
Sex effects across the lifespan in women with multiple sclerosis 39
Sars-CoV2 infection in pregnant women with multiple sclerosis 38
Do we have enough evidence for recommending therapeutic apheresis for natalizumab-related progressive multifocal leukoencephalopathy patients? Comment on "Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for apheresis: The seventh special issue." 38
MRI activity and extended interval of Natalizumab dosing regimen: a multicentre Italian study 37
Gender-related differences in functional connectivity in multiple sclerosis 37
Treatment modifiers across different regimens of natalizumab treatment in MS: an Italian real-world experience 35
Cognitive Impairment in Relapsing-Remitting Multiple Sclerosis Patients with Very Mild Clinical Disability 35
Dorsolateral medullary ischemic infarction causing autonomic dysfunction and headache: a case report 34
Functional connectivity changes in multiple sclerosis patients: a graph analytical study of MEG resting state data 34
Optimizing the "Time to pregnancy" in women with multiple sclerosis: the OPTIMUS Delphi survey 34
fMRI-vs-MEG evaluation of post-stroke interhemispheric asymmetries in primary sensorimotor hand areas 33
A disease-specific convergence of host and Epstein-Barr virus genetics in multiple sclerosis 33
Topographical Correlation between Structural and Functional Impairment of the Macular Inner Retinal Layers in Multiple Sclerosis Eyes with a History of Optic Neuropathy 32
Exposure to natalizumab during pregnancy and lactation is safe - Yes 29
Structural and Functional Assessment of the Macular Inner Retinal Layers in Multiple Sclerosis Eyes Without History of Optic Neuropathy 28
Switch from sequestering to anti-CD20 depleting treatment: disease activity outcomes during wash-out and in the first 6 months of ocrelizumab therapy 27
Therapeutic choices and disease activity after 2 years of treatment with cladribine: an Italian multicenter study (CladStop) 26
Pregnancy effect on disease activity in women with multiple sclerosis treated with cladribine 24
Impact of COVID-19 on pregnancy and fetal outcomes in women with multiple sclerosis 23
Do we have enough evidence for recommending therapeutic apheresis for natalizumab-related progressive multifocal leukoencephalopathy patients? Comment on "Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for apheresis: The seventh special issue." 20
Ocrelizumab in MS patients with persistence of disease activity after alemtuzumab: A multi-center Italian study 18
Treatment discontinuation in older patients with multiple sclerosis 11
null 5
null 3
Totale 9.007
Salva come PNG Salva come JPEG
Categoria #
all - tutte 40.135
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 40.135
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021478 0 0 0 0 0 119 140 106 31 36 29 17
2021/2022379 29 28 20 40 23 48 14 22 34 27 23 71
2022/20231.104 38 30 286 193 48 178 119 47 74 12 59 20
2023/2024451 101 10 22 23 32 64 35 12 28 23 11 90
2024/20252.078 61 375 180 142 62 212 144 88 220 273 180 141
2025/20261.497 274 214 397 199 324 89 0 0 0 0 0 0
Totale 9.007